Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib Plus Temozolomide in Children With Refractory or Recurrent Malignancies
NCT02116777Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in solid tumor, Ewing sarcoma, primitive neuroectodermal tumor (PNET), sponsored by National Cancer Institute. Started May 2014; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumorEwing sarcomaprimitive neuroectodermal tumor (PNET)
Beyond the preview
Go deeper on NCT02116777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116777.